Fayette, J., Popovtzer, A., Forster, M. D., Adkins, D., Guo, Y., Lefebvre, G., Thomas, J. S., Collinson, F. J., Doucet, L., Bouganim, N., Liu, L., Bennouna, J., Gregory, R. C., Li, C., Ramesh, R., Wu, B., Raizer, J., Huang, Y., Sukari, A. (2025). Dose expansion data from iintune-1, a phase 1/2 study of the STING agonist dazostinag plus pembrolizumab as first-line (1L), in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (RM-SCCHN).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.6020